Based on these findings, we hypothesize that: nPAK4 inhibits ERα-DNA-binding and reduces ERα-mediated transcriptional responses in an E2-dependent manner in ERα+ breast cancer patients. This evidence concerns the gene ESR1 and breast carcinoma.